title: Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty.
abstract: Early clinical trials of eptifibatide did not show a significant association between eptifibatide and the development of thrombocytopenia, thrombosis, or disseminated intravascular coagulation. However, more recent literature has suggested a significant association between eptifibatide and the development of thrombocytopenia and thrombosis. Although the true incidence and the pathophysiology of these associations are unknown, the development of these events can be life-threatening. Herein, we describe the case of a patient who experienced acute onset of profound thrombocytopenia, developing thrombosis, pulmonary emboli, and disseminated intravascular coagulation. This paper adds to the few previous reports of cases that suggested an association between thrombocytopenia, thrombosis, and the administration of eptifibatide. To the best of our knowledge, this is the first case report in the medical literature that associates the new onset of thrombocytopenia, thrombosis, and disseminated intravascular coagulation with the administration of eptifibatide. We also provide a subject review.
authors.affiliation: Division of Cardiology, Bluhm Cardiovascular Institute at Northwestern Memorial Hospital, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA. m-tempelhof@md.northwestern.edu
authors.forename: Michael W
authors.initials: MW
authors.lastname: Tempelhof
authors.forename: Keith H
authors.initials: KH
authors.lastname: Benzuly
authors.forename: Dan
authors.initials: D
authors.lastname: Fintel
authors.forename: Marc Z
authors.initials: MZ
authors.lastname: Krichavsky
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation; D000925:Anticoagulants / Q000627:therapeutic use; D001780:Blood Coagulation Tests; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D057915:Drug Substitution; D054855:Drug-Eluting Stents; D000077542:Eptifibatide; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008297:Male; D010455:Peptides / Q000009:adverse effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D010976:Platelet Count; D011237:Predictive Value of Tests; D011655:Pulmonary Embolism / Q000097:blood / Q000139:chemically induced; D012720:Severity of Illness Index; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D013927:Thrombosis / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D013997:Time Factors; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D000077542:Eptifibatide